National Comprehensive Cancer Network

About NCCN

NCCN Guidelines and Compendium Updated

NCCN Flash Updates™ sent March 6, 2013

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hodgkin Lymphoma. These NCCN Guidelines® are currently available as Version 1.2013.

  • Global Changes
    • International Working Group Response Criteria were replaced with Deauville PET criteria for response assessment and to determine further treatment options.
    • Principles of Radiation Therapy extensively revised.
      • Terminology changed throughout the Guidelines, "involved-field" radiation therapy (IFRT) changed to "involved-site" radiation therapy (ISRT).
  • Classical Hodgkin Lymphoma
    • Stage I-II unfavorable bulky disease
      • ABVD x 2-4 cycles changed from a category 2A recommendation to a category 1 recommendation.
      • BEACOPP x 2 cycles + ABVD x 2 cycles + RT added as a treatment option (category 2A).
  • Lymphocyte-Predominant Hodgkin Lymphoma
    • Observation added as a treatment option for stage IA patients with a completely excised solitary lymph node.
    • Single agent rituximab removed as a treatment option.
    • Treatment recommendations added for refractory and relapsed disease.

For the complete updated versions of the NCCN Guidelines, the NCCN Compendium®, and the NCCN Chemotherapy Order Templates (NCCN Templates®), please visit

To view the NCCN Guidelines for Patients®, please visit

To access free NCCN Guidelines mobile apps for iPhone and Android, visit

Now Available! The Virtual Library of NCCN Guidelines are now formatted for iPad and Android. Visit